Last updated on February 2018

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses

Brief description of study

The purpose of this study is to compare and characterize the efficacy and safety of ponatinib in participants with resistant chronic myeloid leukemia (CML) in chronic phase (CP) in a range of doses.

Detailed Study Description

This is a multi-center, randomized, phase 2 trial to characterize the safety and efficacy of ponatinib over a range of 3 starting doses. Eligible participants must have chronic phase chronic myeloid leukemia (CP-CML) and have demonstrated resistance to treatment or have the T315I mutation.

Clinical Study Identifier: NCT02467270

Contact Investigators or Research Sites near you

Start Over

Shinya Kimura

Saga University Hospital (Site 420)
Saga, Japan
  Connect »